|
|
 |
|
Viewing report
|
|
|
|
Laboratory Corporation of America Holdings (LH) - Financial and Strategic SWOT Analysis Review
GlobalData, March 2012, Pages: 46
Laboratory Corporation of America Holdings (LH) - Financial and Strategic SWOT Analysis Review
Summary
Laboratory Corporation of America Holdings (LabCorp) is an independent clinical laboratory company engaged in developing and commercializing a wide range of diagnostic technologies and testing services helping in the routine testing, patient diagnosis, and in the monitoring and treatment of various diseases. The company also offers specialty testing services in the areas of allergy, identity, diagnostic genetics, forensics, oncology, infectious diseases and occupational testing. LabCorp has a network of branches along with 54 primary laboratories and more than 1,700 patient service centers. The key subsidiaries of the company include Dianon Systems, Dynacare Laboratories, Esoterix Laboratory Services, Integrated Genetics, Integrated Oncology, Litholink, Monogram Biosciences, National Genetics Institute, Viromed Laboratories. The major clients of the company are managed care organizations, physicians, hospitals, government agencies and biotechnology and pharmaceutical companies spread across all the 50 states in the US, the District of Columbia, Belgium, Puerto Rico, Japan, China, Singapore, the UK and three Canadian provinces. LabCorp is headquartered in Burlington, North Carolina, the US.
The company focuses on expanding its service portfolio through both inorganic and organic approaches. The inorganic approach includes acquisitions which can be reflected from the recent acquisition of Orchid Cellmark Inc. The organic approach includes in-house development of testing technologies such as the recent launch of ROMA (Risk of Ovarian Malignancy Algorithm), Vysis ALK Break Apart FISH Probe assay and BRAF Gene Mutation Assay. These concentrated efforts will enable the company gain more market share along with better catering of clients.
Laboratory Corporation of America Holdings Key Recent Developments
Jan 18, 2012: LabCorp To Offer New FDA Cleared Test To Aid In Assessing Whether Ovarian Mass Is At High Or Low Likelihood Of Being Malignant
Oct 20, 2011: LabCorp Reports Net Sales Of $1.4 Billion In Q3 2011
Sep 08, 2011: LabCorp Extends Agreement With UnitedHealthcare
Jul 21, 2011: LabCorp Reports Net Sales Of $1.4 Billion In Q2 2011
May 11, 2011: Diasorin And Labcorp Extend Strategic Business Relationship
This comprehensive SWOT profile of Laboratory Corporation of America Holdings provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
|
|
|
|
